The Peptide Daily Brief
A source-linked briefing on consumer peptides, clinical research, regulation, safety, and the health trends shaping public attention.
Peplexicon checks authoritative records nightly. An edition appears only when the system finds a material change, validates the source-bound claim, and admits that claim to the current public profile. Quiet nights do not become filler articles.
You can inspect the operating rules in our editorial policy and the live workflow on the research status page.
Research lab
Our own exploratory analysis of published measurements, reported daily, including unchanged, skipped and degraded runs. These are not verified claims and are kept separate from the Daily Brief above. We publish failures and inconclusive results alongside wins, and every result is stored in an append-only ledger.
0 experiments ran on 661 published measurements (GLP-1 receptor); 0 development results cleared the corrected threshold. Targets: 0 updated, 1 unchanged, 0 skipped, 0 degraded.
No new results
661 published measurements · 549 for development · 112 assigned to the held-out set
Exploratory research notes. They describe analyses of published measurements on therapeutic peptides. They are not verified claims, not health advice, and say nothing about whether any peptide is safe or effective in people. Peplexicon's research lab is non-commercial and educational.
11 experiments ran on 661 published measurements (GLP-1 receptor); 1 development results cleared the corrected threshold. Targets: 1 updated, 0 unchanged, 0 skipped, 0 degraded.
New results
661 published measurements · 549 for development · 112 assigned to the held-out set
Insufficient evidence to reach a conclusion. Median rank correlation: 0.113. Uncertainty interval unavailable. Fewer-edits baseline: 0.225. Evaluated 4 papers and 87 measurements.
p = 0.009 · needed ≤ 2.7e−5
Train on papers up to a cut-off year, then rank the compounds in later papers.
Insufficient evidence to reach a conclusion. Median rank correlation: 0.0913. Uncertainty interval unavailable. Fewer-edits baseline: 0.425. Evaluated 3 papers and 59 measurements.
p = 0.082 · needed ≤ 2.5e−5
Train on papers up to a cut-off year, then rank the compounds in later papers.
Insufficient evidence to reach a conclusion. Median rank correlation: -0.131. Uncertainty interval unavailable. Fewer-edits baseline: 0.195. Evaluated 1 papers and 48 measurements.
p = 1.000 · needed ≤ 2.3e−5
Train on papers up to a cut-off year, then rank the compounds in later papers.
Insufficient evidence to reach a conclusion. Median rank correlation: 0.222. Uncertainty interval unavailable. Fewer-edits baseline: 0.267. Evaluated 2 papers and 35 measurements.
p = 0.345 · needed ≤ 2.1e−5
Train on papers up to a cut-off year, then rank the compounds in later papers.
Insufficient evidence to reach a conclusion. Median rank correlation: 0.577. Uncertainty interval unavailable. Fewer-edits baseline: 0.577. Evaluated 1 papers and 8 measurements.
p = 0.716 · needed ≤ 1.9e−5
Train on papers up to a cut-off year, then rank the compounds in later papers.
Insufficient evidence to reach a conclusion.
Train on papers up to a cut-off year, then rank the compounds in later papers.
Insufficient evidence to reach a conclusion.
Check whether the edits reported most often before a cut-off year are the edits used in later papers.
Did not clear the corrected threshold; this does not establish that an effect is absent. 9 of 15 edits reappeared; 5 expected under the random-draw baseline. This measures literature reuse, not biological efficacy. No uncertainty interval is estimated for this count.
p = 0.004 · needed ≤ 4.1e−5
Check whether the edits reported most often before a cut-off year are the edits used in later papers.
Cleared the corrected threshold. 13 of 15 edits reappeared; 5.54 expected under the random-draw baseline. This measures literature reuse, not biological efficacy. No uncertainty interval is estimated for this count.
p = 3.3e−5 · needed ≤ 3.6e−5
Check whether the edits reported most often before a cut-off year are the edits used in later papers.
Did not clear the corrected threshold; this does not establish that an effect is absent.
p = 0.178 · needed ≤ 0.006
Ask Jev which of two compounds measured side by side is more potent, in both orders, and check its calibration.
Insufficient evidence to reach a conclusion.
Repeat a development win on papers held out from all tuning.
Exploratory research notes. They describe analyses of published measurements on therapeutic peptides. They are not verified claims, not health advice, and say nothing about whether any peptide is safe or effective in people. Peplexicon's research lab is non-commercial and educational.